Also known as: OLUMIANT
Baricitinib is an oral immunomodulatory medicine marketed as Olumiant and used for conditions including rheumatoid arthritis, alopecia areata, and hospitalized COVID-19. It is a Janus kinase inhibitor targeting JAK1 and JAK2 pathways. The drug is approved in the U.S. and EU and is prescription-only.
HHS launches broad initiative to boost US clinical trials amid global competition with China. FDA introduces real-time clinical trial monitoring and expedited programs. NIH Long COVID trials set to begin enrolling participants in summer 2026.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07608796 |
JAK Signaling in Depression and Cognition in Male Football Players |
NOT_YET_RECRUITING | PHASE2 |
| NCT07543458 |
Therapeutics for Moderate and Severe Dengue |
NOT_YET_RECRUITING | PHASE3 |
| NCT07535645 |
Baricitinib for Post-HSCT Persistent Thrombocytopenia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07448363 |
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica |
NOT_YET_RECRUITING | |
| NCT07357649 |
Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07268534 |
Biologics in Folliculitis Decalvans : an Adaptative Trial Research |
NOT_YET_RECRUITING | PHASE2 |
| NCT07262983 |
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis |
RECRUITING | PHASE1 |
| NCT07222332 |
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) |
RECRUITING | PHASE3 |
| NCT07222137 |
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults |
RECRUITING | PHASE3 |
| NCT07003997 |
JAK Signaling in Depression |
RECRUITING | PHASE2 |
